It has long been known that marihuana consumption acutely increases appetite (Hollister,
1971) and decreases body temperature (Borgen et al., 1973). These effects predicted that …

There is growing interest in the commercialisation of the CB1 receptor antagonist
Rimonabant in Europe for the treatment of obesity and the metabolic syndrome. Clinical …

The endocannabinoid system elicits multiple physiologic functions that are not fully
understood. Antagonism of cannabinoid type 1 (CB1) receptors has been the only …

Obesity represents the most prevalent metabolic disease in the world at present, posing an
important public health challenge. This circumstance has led to a better understanding of the …

Purpose of review The purpose of the review was to revisit the possibility of the
endocannabinoid system being a therapeutic target for the treatment of obesity by focusing …

Two receptors have been cloned to date for the psychotropic compound Δ 9-
tetrahydrocannabinol, and termed cannabinoid CB 1 and CB 2 receptors. Their endogenous …

Endocannabinoids and cannabinoid CB1 receptors are known to play a generalized role in
energy homeostasis. However, clinical trials with the first generation of CB1 blockers, now …

Presentations in this symposium addressed effects and modes of action of
endocannabinoids in various tissues in relation to metabolic disorders. Endocannabinoids …

The endocannabinoid system (ECS), including cannabinoid type 1 and type 2 receptors
(CB1R and CB2R), endogenous ligands called endocannabinoids and their related …

The endocannabinoid system is a complex system with endogenous ligands, synthesis and
transport processes, specific receptors (CB1 and CB2) and intracellular degrading enzymes …